Optimizing patient access with evidence of product value, effectiveness, and safety from early development through loss of exclusivity.

Learn More
Latest News

The Fall Issue of The Evidence Forum is Out

Read content related to the relevant issues facing companies along the path to approval and access

Read Now
Upcoming Virtual Meeting

ISPOR Europe 2020

With 50 presentations – including workshops, issue panels, podium, and posters – our thought leaders are speaking to important and relevant topics affecting our industry

Learn More
Latest News

Committed to Supporting Clients During the COVID-19 Pandemic

Access resources and information related to COVID-19 studies to discover how we are joining the COVID-19 fight

Learn More
ClinicaLive
ClinicaLive™

Rapid Access to Global Patient-Level Data

Discover our new chart review methodology that combines our proprietary access to a global network of HCPs with robust epidemiological methods and decades of project delivery excellence – ClinicaLive™

Learn More
Upcoming Webinar Series

Global Genes Three-Part Webinar Series

Discover five core guiding principles to use as a set of fundamental expectations for rare disease patient care and access
Co-sponsored by Global Genes and the Child Neurology Foundation in partnership with NAMCP

Learn More

Our Work In Action

150+ Drugs/Therapies

supported in the past year

30+ Global Extended Access Programs

in the last 3 years alone with thousands of patients transitioning smoothly from investigational to commercial

130+ Payer Submissions

across 20+ countries in the past 5 years, including reversal of multiple NICE decisions

17 of the 20 Top-Selling Drugs

in 2018 supported in the past 5 years

130+ Peer-Reviewed Publications

and 220+ research posters and presentations per year

Learn More

Latest Publications

Dermatology

Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial

  • JAMA Dermatology
  • October 2020
Oncology

STK11 (LKB1) Mutations in Metastatic NSCLC: Prognostic Value in the Real World

  • PLoS One
  • October 2020
Neurology

Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients With Relapsing-Remitting Multiple Sclerosis

  • Advances in Therapy
  • October 2020
Read More About Our Publications
What We Do

What We Do

Real-World Evidence & Data Solutions

Obtain real-world evidence to optimize product value, effectiveness, safety, and market strategy by extracting data from existing sources, collecting primary data, and conducting hybrid studies.

Non-Interventional Studies

Robust design, epidemiologic and therapeutic area insights, advanced data analytics and precision study execution critical for study and program success.

Interventional Studies

Provide peri- and post-approval evidence via dedicated global operations and custom-tailored study designs.

Patient-Centered Research

Develop and evaluate clinical outcomes assessments to support labeling and promotional claims.

Evidence Synthesis, Modeling & Communication

Provide a truly connected value story, supported by strong evidence

Value & Development Consulting

End-to-end regulatory, clinical development, and value and access consulting services that span all phases of development.

Medical Writing

Expert medical writing, including medical information, study documentation, and publications, tailored to the peri- and post-approval environment.

In Our Own Words

There is an increasing desire from regulators and HTA bodies to provide patient-centric integrated scientific advice (ISA) earlier in the technologies development process. Our ISA offering supports clients by generating evidence that meets all stakeholder needs, ensuring timely patient access and commercial success.

Case Study

Virtual Expanded Access Program Providing Breast Cancer Patients Early Access to Treatment During the COVID-19 Pandemic

Evidera was able to provide a virtual approach to mitigate the risk to patient safety in the COVID-19 pandemic and enabled early patient access to 400 US breast cancer patients ahead of commercial availability.

Read More
Case Study

Enhancing Oncology Market Access with a Real-World Evidence EAMS Add-on

Discover how Evidera researchers designed an observational study to conceptualize and implement real-world data collection in an Early Access to Medicines Scheme (EAMS) for an oncology therapy.

Read More
Case Study

Evidera Led Effort to Qualify the First Biomarker for COPD Trial Enrichment

Learn how Evidera's partnership with the COPD Foundation Biomarker Qualification Consortium led to the qualification of plasma fibrinogen as the first biomarker in COPD for enrichment of clinical trials by the FDA.

Read More
Careers

Meaningful Work at Every Level

We assess candidates across a variety of scientific and operational functions. From leaders in their fields, to those who are new to the industry. We employ people who have a proactive mind-set when it comes to the work they do and helping the people they work with.

Learn More